87 Tex. L. Rev. 503 (2008-2009)
Unpatentable Drugs and the Standards of Patentability

handle is hein.journals/tlr87 and id is 511 raw text is: Texas Law Review
Volume 87, Number 3, February 2009
Articles
Unpatentable Drugs and the Standards of
Patentability
Benjamin N. Roin
The role of the patent system in promoting pharmaceutical innovation is
widely seen as a tremendous success story. This view overlooks a serious short-
coming in the drug patent system: the standards by which drugs are deemed
unpatentable under the novelty and nonobviousness requirements bear little re-
lationship to the social value of those drugs or the need for a patent to motivate
their development. If the idea for a drug is not novel or is obvious-perhaps
because it was disclosed in an earlier publication or made to look obvious by
recent scientific advances-then it cannot be patented. Yet, the mere idea for a
drug alone is generally of little value to the public. Without clinical trials prov-
ing the drug's safety and efficacy, which is a prerequisite for approval by the
Food and Drug Administration (FDA) and acceptance by the medical
community, that drug is unlikely to benefit the public. Given the immense
investment needed to fund clinical trials on drugs and the ability of generic
manufacturers to rely on those tests to secure regulatory approval for their own
products, pharmaceutical companies are rarely willing to develop drugs without
patent protection. The novelty and nonobviousness requirements make no con-
cession for the development costs of inventions and thus cause patents to be
withheld from drugs that are unlikely to reach the public without that protection.
This gap in the patent system for drugs has created a pervasive problem in the
pharmaceutical industry, causing firms to regularly screen their drugs during
the research-and-development process and discard ones with weak patent
protection. The harm to the public from the loss of these drugs is potentially
quite significant. Congress can easily avoid this problem by ensuring that the
successful completion of the FDA's rigorous clinical-trial process is rewarded
with a lengthy exclusivity period enforced by the FDA.

What Is HeinOnline?

HeinOnline is a subscription-based resource containing nearly 2,700 academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.



Short-term subscription options include 24 hours, 48 hours, or 1 week to HeinOnline with pricing starting as low as $29.95

Access to this content requires a subscription. Please visit the following page to request a quote or trial:

Already a HeinOnline Subscriber?